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Estimation of glomerular filtration rate (GFR) using the clearance of chromium 51 EDTA (
51Cr-EDTA) (or other radiolabelled
isotopes) is reliable, but invasive and not always practicable. Mathematical models have been devised for estimating GFR using readily
obtainable patient characteristics. Unfortunately, these models were developed using various patient populations and may not
provide the optimal prediction of GFR in children with cancer. The current study uses population pharmacokinetics to determine the
relationship between
51Cr-EDTA clearance, and patient covariates in 50 paediatric cancer patients. These models were validated
using a separate group of 43 children and were compared with previously published models of renal function. Body size was the
major determinant of
51Cr-EDTA clearance and inclusion of weight or surface area reduced the residual variability between
individuals (coefficient of variation) from 61 to 32%. Serum creatinine was the only other parameter that significantly improved the
model. Mean percentage error values of –5.0 and –1.1% were observed for models including weight alone or weight and creatinine,
respectively, with precision estimates of 21.7 and 20.0%. These simple additive models provide a more rationale approach than the
use of complex formulae, involving additional parameters, to predict renal function.
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Assessment of the glomerular filtration rate (GFR) is widely
accepted as the best index of renal function in patients. Many
chemotherapeutic drugs are excreted to a large extent via the
kidneys, thus a reliable and accurate measurement of this
parameter is particularly important in oncology practice. The
relationship between kidney function and the extent of drug
exposure is best exemplified by carboplatin, where the dose of
drug administered is determined by renal function in both adult
and paediatric patients (Calvert et al, 1989; Newell et al, 1993;
Thomas et al, 2000). In addition, a measurement of renal function
may be important in monitoring the nephrotoxic effects of drugs
such as cisplatin and ifosfamide (Skinner et al, 1994).
An accurate determination of GFR can be obtained by
measuring the clearance of chromium 51 EDTA (
51Cr-EDTA) or
similar isotope-based methods (Chantler et al, 1969; Rodman et al,
1993). This approach would be recommended when an accurate
prediction of GFR is required, particularly in patients with reduced
renal function. However, EDTA is not licenced for use in countries
such as the USA. Alternatively, GFR can be estimated from serum
creatinine concentration or calculated creatinine clearance (Per-
rone et al, 1992). These latter methods offer a less precise
estimation of renal function, but can generally be performed with
minimum patient inconvenience and at a lower cost than the
isotopic methods. In paediatrics, problems may arise as these
methods have commonly been validated in adults and it is difficult
to obtain an accurate collection of urine over a 24-h period. A
noninvasive, simple and reliable mathematical model for predict-
ing GFR in a paediatric patient population would be advantageous,
particularly if the withdrawal of multiple blood samples could be
avoided.
Several mathematical equations and nomograms have been
developed to predict renal function (Jelliffe, 1973; Cockcroft and
Gault, 1976; Schwartz et al, 1976). The most commonly used of
these formulae to predict creatinine clearance, and hence GFR, in
adult patients have been those published by Cockcroft and Gault
and that of Jelliffe, using age, sex, serum creatinine and either body
weight (Cockcroft and Gault) or surface area (Jelliffe) as a measure
of body size. In paediatric patients, perhaps the most widely used
is that described by Schwartz, which is based on the ratio of height
to serum creatinine concentration and includes an adjustment for
patient age (Schwartz et al, 1976).
Whereas in adult patient populations these formulae approx-
imate GFR to an acceptable level (Luke et al, 1990), similar studies
in paediatric patient populations have highlighted inaccuracies. In
a study involving patients aged between 2 and 18 years, 95% of
GFR estimates obtained from the Schwartz formula would be
expected to lie within 50% of the GFR determined as the clearance
of
51Cr-EDTA (Skinner et al, 1994). In clinical practice, a higher
level of accuracy is often required and the use of these models has
been associated with inaccurate dosing of carboplatin (Calvert and
Egorin, 2002).
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lThe statistical methodology routinely used to model
51Cr-EDTA
pharmacokinetics does not take into account the sampling
variability in the estimates of
51Cr-EDTA clearance. For this
reason, approaches based on nonlinear mixed effects models, often
referred to as population models, have recently been published and
independently assessed (Martin et al, 1998; Wright et al, 2001;
Poole et al, 2002; Le ´ger et al, 2002). These methods involve the use
of patient specific
51Cr-EDTA plasma data together with supple-
mentary covariate information. The current study applies non-
linear mixed effects modelling to the pharmacokinetics of
51Cr-
EDTA, with a view to predicting GFR in paediatric cancer patients.
MATERIALS AND METHODS
Patients
Data were collected retrospectively on a total of 93 patients (50
male, 43 female) diagnosed between 1990 and 2000 and treated for
cancer at the Royal Victoria Infirmary in Newcastle upon Tyne,
UK. All of the patients had undergone assessment of renal function
via
51Cr-EDTA clearance; a blood sample for biochemical analysis
had also been taken at the same time. Biochemical analysis
included the determination of levels of sodium, potassium, urea,
albumin, total protein and bilirubin. The Boyd formula (Boyd,
1935) as recommended by Sharkey et al (2001) was used to
estimate body surface area in this study.
There were a wide variety of malignancies including 35 bone, 26
soft-tissue sarcoma, 13 neuroblastoma and 10 germ cell tumours
(Table 1). None of the patients had undergone a nephrectomy.
Ages ranged from 10 months to 19.8 years.
51Cr-EDTA clearance data
Following an intravenous bolus administration of
51Cr-EDTA,
three plasma samples were taken at approximately 1, 2 and 4h. The
first sample was taken at a median time of 67min (range, 55–
135min), the second at 129min (109–247min) and the third at
247min (187–395min).
51Cr-EDTA clearance was assumed to be an accurate measure of
GFR and is subsequently referred to as such. Glomerular filtration
rate was estimated by fitting a linear least-squares regression to the
logarithmically transformed counts per minute per ml
(c.p.m.ml
 1) vs time data. Assuming a one-compartment model
for
51Cr-EDTA pharmacokinetics, the elimination rate constant (k)
is estimated by the negative of the slope of the regression line,
while the volume of distribution (Vd) is estimated by the ratio of
the injected c.p.m. to the estimated c.p.m.ml
 1 at time zero.
Glomerular filtration rate is calculated as the product of k and Vd.
Population models for
51Cr-EDTA
Of the 93 patients, 50 were randomly assigned to a modelling data
set used to derive the population model for
51Cr-EDTA; the
remaining 43 were assigned to a validation data set used to assess
the ability of the models to predict GFR. Data from patients
assigned to the validation set were not used to derive the
population model.
The development of a population model for
51Cr-EDTA was
undertaken using the first-order conditional estimation method
implemented as a part of the NONMEM Version V level 1.1
software (Boeckmann et al, 1997). The following general modelling
strategy was employed; however, there was inevitably an iterative
element to the process: (i) appropriate structural and error models
were determined; (ii) models to account for variation in clearance
due to ‘body size’ were examined; and (iii) a forward selection
strategy was used to account for variation in clearance not
accounted for by ‘body size’; covariates considered were sex,
sodium, potassium, urea, albumin, total protein and bilirubin.
Choices concerning model structure and covariate selection were
based on the reduction in NONMEM objective function value and
interindividual variability, together with the examination of
residual plots. Finally, the functional forms of other clearance
models based on previously published studies were investigated.
Model validation
Glomerular filtration rate was estimated for each individual in the
validation data set using each of the candidate
51Cr-EDTA
population clearance models and each of the previously published
GFR estimation methods. The percentage error and precision of
the various methods, relative to GFR as determined by the
standard
51Cr-EDTA clearance method, were assessed by the mean
percentage error (MPE) and mean absolute percentage error,
respectively. The limits of agreement were calculated for the
percentage error (Bland and Altman, 1986).
RESULTS
Population models for
51Cr-EDTA
There were no apparent differences between the ‘modelling’ and
‘validation’ groups in terms of age, weight and height profiles, or in
the distribution of the biochemical measurements (Tables 1 and 2).
Median GFR was 76mlmin
 1 with a range of 12–198mlmin
 1
(Table 2), and the frequency distribution of GFR in all the patients
studied is given in Figure 1.
51Cr-EDTA pharmacokinetics were adequately described by a
one-compartment model, intrasubject variation by an additive
error model and between-subject variation in both clearance and
Vd by an exponential error model.
Clearance of
51Cr-EDTA was strongly related to body size. The
coefficient of variation (CV) in the between-subject error for
clearance was reduced from 61 to 32% when either BSA or weight
was included in the model. Various transformations of BSA
and weight were considered, for example logarithmic, but none of
these improved the fit of the model beyond a simple additive term.
Weight, rather than BSA, was retained in the model (Table 3)
as estimates of BSA are often based on weight and height,
with height being difficult to estimate in small children (Sharkey
et al, 2001).
None of the remaining potential covariates significantly reduced
the CV in the between-subject error for clearance, with the
exception of serum creatinine. Various transformations for serum
creatinine were considered, but a simple additive term again
proved to be sufficient (Table 3), resulting in a further reduction of
the CV to 28%. At this stage none of the other variables, including
Table 1 Summary of patient characteristics
Variable Modelling data set Validation data set
Number of patients 50 43
Number o1 year 2 0
Number o10kg 3 3
Sex (male/female) 26/24 24/19
Diagnosis
Bone 22 13
Carcinoma 1 1
Germ cell 3 7
Neuroblastoma 6 7
Soft-tissue sarcoma 14 12
Other 4 3
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lage and sex, improved the fit of the model. Although serum
bilirubin had the next biggest impact on improving the fit, the
addition of this variable was far from statistically significant.
Comparison of models
The various models for
51Cr-EDTA clearance used to assess
predictive performance are shown in Table 3. The ‘weight’ and
‘creatinine’ models are the population models obtained from this
study. The equations labelled ‘Cockcroft function’ and ‘Jelliffe
function’ were obtained by using the functional form of previously
published models that were derived in adults. As applied here, the
coefficients were re-estimated using the current modelling data set.
The coefficients in the Schwartz and Le ´ger models are those that
have been published previously, as these were derived from a
paediatric population.
The ‘weight’ model predicts an increase in GFR of 1.67mlmin
 1
for a 1kg increase in body weight. For a ‘typical’ 10kg child this
relates to a 5% increase in GFR, and a 1% increase for a ‘typical’
70kg child. Similarly, given a 5mmoll
 1 increase in serum
creatinine, the ‘creatinine’ model predicts a 7% decrease in GFR
for a 10kg child with a serum creatinine of 45mmoll
 1 (roughly
the median serum creatinine level for a child of this weight). For a
larger 70kg child with a serum creatinine of 75mmoll
 1, the
‘creatinine’ model predicts a 2% decrease in GFR for the same
5mmoll
 1 increase in serum creatinine.
A comparison of the percentage error of the various formulae
using the validation set (together with the limits of agreement) is
presented in Table 4; 95% of values would be expected to lie within
these limits. Figure 2 shows the percentage error plotted against
GFR for each equation. Two patients who had GFRs less than
25mlmin
 1 were excluded from the statistical analysis of the
validation set, although their data are shown in Figure 2.
The Le ´ger, Jelliffe and the creatinine models have the smallest
percentage error, although the 95% confidence intervals are
relatively wide. The Schwartz and weight models tend to under-
estimate, while the Cockcroft model tends to overestimate;
Table 2 Comparison of modelling and validation sets with regard to all covariates
Modelling data set Validation data set All patients
Variable Median Range Median Range Median Range
Age (years) 10.5 (0.8–19.8) 8.7 (1.0–19.3) 10.3 (0.8–19.3)
Weight (kg) 33.2 (8.4–93.7) 25.0 (8.0–80.0) 31.1 (8.0–93.7)
Height (cm) 144 (72–194) 130 (74–191) 142 (72–194)
Body surface area (m
2) 1.12 (0.44–2.25) 0.92 (0.42–2.02) 1.07 (0.42–2.25)
Serum creatinine (mmoll
 1) 59.5 (32–99) 57 (24–89) 58 (24–99)
Sodium (mmoll
 1) 139 (130–145) 139 (126–143) 139 (126–145)
Potassium (mmoll
 1) 4.2 (3.3–5.0) 4.2 (3.6–5.5) 4.2 (3.3–5.5)
Urea (mmoll
 1) 3.8 (1.5–6.8) 4.0 (1.5–7.0) 3.9 (1.5–7.0)
Albumin (gl
 1) 41 (27–48) 41 (25–50) 41 (25–50)
Protein (gl
 1) 68 (57–80) 65 (50–78) 68 (50–80)
Bilirubin (mmoll
 1) 8 (2–20) 8 (3–51) 8 (2–51)
51Cr-EDTA clearance (mlmin
 1) 74 (14–198) 80 (12–178) 76 (12–198)
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Figure 1 Distribution of GFR in all patients studied.
Table 3 Formulae to predict GFR (mlmin
 1)
Model Equation
Creatinine model 36.76+1.91 Wt 0.47 SCr
Weight model 16.25+1.67 Wt
Cockcroft function
a ð130 þ 0:09 AgeÞ Wt ð1 þ 0:11 SexÞ
SCr
Jelliffe function
a ð2530 þ 126 AgeÞ BSA ð1 þ 0:13 SexÞ
SCr
Le ´ger model ð56:7 Wt þ 0:142 Hght2Þ
SCr
Schwartz regression 0:55 Hght
SCr 0:01131
 ðBSA=1:73Þ if female
1:5 Ageþ
0:5 Hght
SCr 0:01131

 ðBSA=1:73Þ if male
Coefficients derived from modelling data set, except for Schwarz and Le ´ger equations
where the original coefficients are used. Wt: weight (kg); Age: age (years); Sex: 1 if
male, 0 if female; SCr: serum creatinine (mmoll
 1); BSA: body surface area (m
2); Hght:
height (cm).
aCoefficients re-estimated from current data set using nonlinear mixed
effects modelling.
Table 4 Comparison of formulae percentage error and limits of
agreement
Percentage
error
Mean
(95% confidence interval)
95% Limits of
agreement
Creatinine model  1.1 ( 8.9, 6.8)  50, 48
Weight model  5.0 ( 13.3, 3.2)  56, 46
Cockcroft function 3.4 ( 4.3, 11.0)  44, 51
Jelliffe function 1.2 ( 6.1, 8.4)  44, 46
Le ´ger 0.0 ( 6.8, 6.9)  43, 43
Schwartz regression  5.8 ( 13.3, 1.7)  52, 41
Percentage error is defined as 100[(estimated GFR–actual GFR)/(actual GFR)]. The
actual GFR is obtained from the clearance of
51CR-EDTA. In all, 95% of values would
be expected to lie within the limits of agreement.
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lhowever, none of the models showed a statistically significant
percentage error. Also, none of the models have a statistically
significantly smaller percentage error than any other model (data
not shown). The 95% limits of agreement are wide in each case, the
typical range being –50%, 50%. This implies that 5% of estimated
GFRs would be expected to differ from the true value by more than
50%.
The precision of the various equations is shown graphically in
Figure 3. Again, there is no significant difference between the
various models, with median precision values of approximately
20%.
DISCUSSION
An accurate estimation of renal function in children is important
in optimising the dose of many drugs used in paediatric oncology,
and allows clinical monitoring of the nephrotoxic effects of
cytotoxic agents such as cisplatin. The current study investigates
the relationship between
51Cr-EDTA population pharmacokinetics
and patient covariates commonly obtained from children with
cancer. Population models for
51Cr-EDTA clearance were derived
from 50 paediatric patients randomly assigned to a modelling data
set and were validated using a separate group of 43 children. The
abilities of these models to predict GFR were compared with the
functional form of previously published creatinine clearance
models. This type of population pharmacokinetic approach for
predicting GFR has previously been used successfully in adults
(Martin et al, 1998; Wright et al, 2001) and in children with renal
disease (Le ´ger et al, 2002).
51Cr-EDTA clearance was strongly correlated to body size, with
a simple additive model (16.25þ1.67 Wt) proving to be as
good a fit as that obtained using more complex transformations
of BSA and weight. Of the remaining parameters, only
serum creatinine was seen to improve the model, as determined
by a significant reduction of the CV in the between-subject
error for clearance. Again, a simple additive term proved to
be as efficient in predicting GFR as any more
complex transformations, giving rise to a refined model
(GFR¼36.76þ1.91 Wt 0.47 SCr). Owing to the significant
variation in body weight in the patient population studied
(range: 8–93.7kg), and the dominant effect of this covariate,
other variables, such as age and sex, failed to improve the fit of
the model. Bilirubin was shown to be the next biggest factor,
but did not significantly improve the fit of the model. Serum
creatinine was highly correlated with weight (data not shown),
such that the predictive power of this covariate was compromised
in this patient group.
The application of the population models developed in this
study to the validation patient group resulted in an MPE of  5.0
and  1.1% for the ‘weight’ and ‘creatinine’ models, respectively.
Precision estimates of 21.7 and 20.0% were obtained for these two
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Figure 2 Comparison of formulae percentage error vs GFR as estimated by the clearance of
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percentage error. Boxplot showing absolute percentage error, excluding
individuals with GFR o25mlmin
 1.
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lmodels, indicating that the use of creatinine in addition to weight
results in a marginally more robust prediction of
51Cr-EDTA
clearance. Adopting the functional forms of established and
commonly used equations, but with coefficients re-estimated
using a paediatric data set, there was little to choose between the
various models in terms of estimated MPE and precision. Slight
variations in the percentage error (mean values ranging from 70.0
to 5.8%) and precision (mean values ranging from 17.5 to 21.7%)
are overshadowed by the wide 95% limits of agreement observed
for all the models investigated, with typical ranges of –50 to 50%.
These results imply that 5% of estimated GFRs would be expected
to be more than 50% discrepant from the true value, are not
dissimilar to those noted previously using the Schwartz equation
and highlight the shortcomings of all the models studied in this
patient population.
Detailed analysis of the current data failed to identify
subpopulations of patients, such as those with unusually high or
low GFR values, in whom a particular model may be more
appropriate. Two patients with very low GFR values (12 and
15mlmin
 1) were excluded from the analysis of the validation set.
These patients were both under 2 years of age weighing 11 and
8kg, respectively. Their serum creatinine levels were 64 and
43mmoll
 1. All of the equations predicted their GFR poorly,
substantially overestimating in each case. For example, the
Cockcroft model predicts 24mlmin
 1 for both patients, an
overestimate of 99 and 61%. For patients with estimated GFR
values less than 40mlmin
 1, it is advisable to obtain a direct
determination of renal function using the
51Cr-EDTA, or similar,
method.
The data presented here, and the models derived from them, are
specific to paediatric cancer patients. Nevertheless, there are
limitations to the use of any of these equations in clinical practice.
Firstly, prospective prediction of GFR using these equations is
unlikely to be as good as in the study in which they were
developed. The models should be used with caution in subgroups
of patients not included in the original validation. In addition,
using prediction equations based on serum creatinine concentra-
tion can be problematic if creatinine concentrations are not at
steady state (Payne, 1986; Perrone et al, 1992). Although the use of
serum cystatin C as a parameter for predicting renal function has
been recently suggested (Stabuc et al, 2000; Dharnidharka et al,
2002), its use in paediatric patients appears to offer few advantages
over that of serum creatinine (Krieser et al, 2002; Willems et al,
2003). While cystatin C measurements were not obtained as a part
of the current study, it seems unlikely that its use would have made
a significant difference to the results obtained.
If a noninvasive estimate of GFR is required in children with
cancer, the formula involving weight and serum creatinine as the
only two variables performs as well as any of the equations that are
commonly used in predicting renal function. Using a linear form
of equation is more rational than the use of more complex
formulae. For situations in which an accurate measurement of
renal function is essential, the determination of GFR as clearance
of
51Cr-EDTA is strongly recommended. Such situations include
using an estimation of GFR to guide the dosing of high-dose
carboplatin chemotherapy, which can result in severe and
potentially life-threatening side effects, and dealing with children
with a reduced renal function.
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